RISS 학술연구정보서비스

검색

인기 검색어

    다국어 입력

    http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

    변환된 중국어를 복사하여 사용하시면 됩니다.

    예시)
    • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
    • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
    닫기
    KCI등재 SCIE SCOPUS

    Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival

    한글로보기

    https://www.riss.kr/link?id=A103914117

    • 0

      상세조회
    • 0

      다운로드
    서지정보 열기
    • 내보내기
    • 내책장담기
    • 공유하기
      • URL 복사
    • 오류접수
    인용문이 복사되었습니다.

    부가정보

    다국어 초록 (Multilingual Abstract) kakao i 다국어 번역

    Objective: To identify CT and FDG-PET features associated with epidermal growth factor receptor (EGFR) protein overexpression, and to evaluate whether imaging features and EGFR-overexpression can help predict clinical outcome.
    Materials and Methods: In 214 patients (M : F = 129 : 85; mean age, 63.2) who underwent curative resection of stage I non-small cell lung cancer, EGFR protein expression status was determined through immunohistochemical analysis. Imaging characteristics on CT and FDG-PET was assessed in relation to EGFR-overexpression. Imaging features and EGFRoverexpression were also evaluated for clinical outcome by using the Cox proportional hazards model.
    Results: EGFR-overexpression was found in 51 patients (23.8%). It was significantly more frequent in tumors with an SUVmax > 5.0 (p < 0.0001), diameter > 2.43 cm (p < 0.0001), and with ground glass opacity ≤ 50% (p = 0.0073). SUVmax > 5.0 (OR, 3.113; 95% CI, 1.375-7.049; p = 0.006) and diameter > 2.43 cm (OR, 2.799; 95% CI, 1.285-6.095; p = 0.010) were independent predictors of EGFR overexpression. Multivariate analysis showed that SUVmax > 4.0 (hazard ratio, 10.660; 95% CI, 1.370-82.966; p = 0.024), and the presence of cavitation within a tumor (hazard ratio, 3.122; 95% CI, 1.1438.532; p = 0.026) were factors associated with poor prognosis.
    Conclusion: EGFR-overexpression is associated with high SUVmax, large tumor diameter, and small GGO proportion. CT and FDG-PET findings, which are closely related to EGFR overexpression, can be valuable in the prediction of clinical outcome.
    번역하기

    Objective: To identify CT and FDG-PET features associated with epidermal growth factor receptor (EGFR) protein overexpression, and to evaluate whether imaging features and EGFR-overexpression can help predict clinical outcome. Materials and Methods: I...

    Objective: To identify CT and FDG-PET features associated with epidermal growth factor receptor (EGFR) protein overexpression, and to evaluate whether imaging features and EGFR-overexpression can help predict clinical outcome.
    Materials and Methods: In 214 patients (M : F = 129 : 85; mean age, 63.2) who underwent curative resection of stage I non-small cell lung cancer, EGFR protein expression status was determined through immunohistochemical analysis. Imaging characteristics on CT and FDG-PET was assessed in relation to EGFR-overexpression. Imaging features and EGFRoverexpression were also evaluated for clinical outcome by using the Cox proportional hazards model.
    Results: EGFR-overexpression was found in 51 patients (23.8%). It was significantly more frequent in tumors with an SUVmax > 5.0 (p < 0.0001), diameter > 2.43 cm (p < 0.0001), and with ground glass opacity ≤ 50% (p = 0.0073). SUVmax > 5.0 (OR, 3.113; 95% CI, 1.375-7.049; p = 0.006) and diameter > 2.43 cm (OR, 2.799; 95% CI, 1.285-6.095; p = 0.010) were independent predictors of EGFR overexpression. Multivariate analysis showed that SUVmax > 4.0 (hazard ratio, 10.660; 95% CI, 1.370-82.966; p = 0.024), and the presence of cavitation within a tumor (hazard ratio, 3.122; 95% CI, 1.1438.532; p = 0.026) were factors associated with poor prognosis.
    Conclusion: EGFR-overexpression is associated with high SUVmax, large tumor diameter, and small GGO proportion. CT and FDG-PET findings, which are closely related to EGFR overexpression, can be valuable in the prediction of clinical outcome.

    더보기

    참고문헌 (Reference)

    1 Sasaki R, "[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer" 23 : 1136-1143, 2005

    2 Yano T, "Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancerspecial reference to tumor size" 5 : 45-48, 2010

    3 Onn A, "Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome" 237 : 342-347, 2005

    4 Berger M, "Thompson JR. Cavitary carcinomatosis of the lungs. Report of a case" 52 : 106-111, 1967

    5 Groome PA, "The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours" 2 : 694-705, 2007

    6 Goldstraw P, "The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours" 2 : 706-714, 2007

    7 Rami-Porta R, "The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer" 2 : 593-602, 2007

    8 Rusch VW, "The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer" 2 : 603-612, 2007

    9 Postmus PE, "The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer" 2 : 686-693, 2007

    10 Giroux DJ, "The IASLC Lung Cancer Staging Project: data elements for the prospective project" 4 : 679-683, 2009

    1 Sasaki R, "[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer" 23 : 1136-1143, 2005

    2 Yano T, "Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancerspecial reference to tumor size" 5 : 45-48, 2010

    3 Onn A, "Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome" 237 : 342-347, 2005

    4 Berger M, "Thompson JR. Cavitary carcinomatosis of the lungs. Report of a case" 52 : 106-111, 1967

    5 Groome PA, "The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours" 2 : 694-705, 2007

    6 Goldstraw P, "The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours" 2 : 706-714, 2007

    7 Rami-Porta R, "The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer" 2 : 593-602, 2007

    8 Rusch VW, "The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer" 2 : 603-612, 2007

    9 Postmus PE, "The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer" 2 : 686-693, 2007

    10 Giroux DJ, "The IASLC Lung Cancer Staging Project: data elements for the prospective project" 4 : 679-683, 2009

    11 Onn A, "Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer" 10 (10): 136-143, 2004

    12 Vazquez M, "Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications" 64 : 148-154, 2009

    13 Suzuki K, "Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact" 81 : 413-419, 2006

    14 Volm M, "Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas" 77 : 663-669, 1998

    15 Takashima S, "Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: a retrospective study on 64 patients" 36 : 289-295, 2002

    16 Chaudhuri MR, "Primary pulmonary cavitating carcinomas" 28 : 354-366, 1973

    17 "Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance" SPRINGER 19 (19): 552-560, 2009

    18 van Klaveren RJ, "Management of lung nodules detected by volume CT scanning" 361 : 2221-2229, 2009

    19 Travis WD, "International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma" 6 : 244-285, 2011

    20 Cappuzzo F, "Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC" 21 : 2658-2663, 2003

    21 Taylor MD, "Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer" 137 : 43-48, 2009

    22 신경민, "FDG PET/CT and Mediastinal Nodal Metastasis Detection in Stage T1 Non-Small Cell Lung Cancer: Prognostic Implications" 대한영상의학회 9 (9): 481-489, 2008

    23 Huang SM, "Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results" 17 : 259-269, 1999

    24 Yano M, "Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma" 1 : 413-416, 2006

    25 Franklin WA, "Epidermal growth factor receptor family in lung cancer and premalignancy" 29 (29): 3-14, 2002

    26 Ohsaki Y, "Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression" 7 : 603-607, 2000

    27 "EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: Investigation of significantly related factors on CT, FDG-PET, and histopathology" Elsevier 64 : 179-186, 2009

    28 Nicholson RI, "EGFR and cancer prognosis" 37 (37): S9-S15, 2001

    29 Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer" 346 : 92-98, 2002

    30 Jeon YK, "Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer" 54 : 387-398, 2006

    31 Pentheroudakis G, "Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features" 45 : 349-355, 2004

    32 Kolodziejski LS, "Cavitated tumor as a clinical subentity in squamous cell lung cancer patients" 50 : 66-73, 2003

    33 Kyung Won Lee, "A New Method of Measuring the Amount of Soft Tissue in Pulmonary Ground-Glass Opacity Nodules: a Phantom Study" 대한영상의학회 9 (9): 219-225, 2008

    더보기

    분석정보

    View

    상세정보조회

    0

    Usage

    원문다운로드

    0

    대출신청

    0

    복사신청

    0

    EDDS신청

    0

    동일 주제 내 활용도 TOP

    더보기

    주제

    연도별 연구동향

    연도별 활용동향

    연관논문

    연구자 네트워크맵

    공동연구자 (7)

    유사연구자 (20) 활용도상위20명

    인용정보 인용지수 설명보기

    학술지 이력

    학술지 이력
    연월일 이력구분 이력상세 등재구분
    2023 평가 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
    2020-01-01 등재 등재학술지 유지 (해외등재 학술지 평가) KCI등재
    2016-11-15 학회명변경 영문명 : The Korean Radiological Society -> The Korean Society of Radiology KCI등재
    2010-01-01 등재 등재학술지 유지 (등재유지) KCI등재
    2007-01-01 등재 등재학술지 선정 (등재후보2차) KCI등재
    2006-01-01 등재 등재후보 1차 PASS (등재후보1차) KCI등재후보
    2003-01-01 등재 등재후보학술지 선정 (신규평가) KCI등재후보
    더보기

    학술지 인용정보

    학술지 인용정보
    기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
    2016 1.61 0.46 1.15
    KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
    0.93 0.84 0.494 0.06
    더보기
    해외이동버튼